Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary
March 12, 2026
Earnings Call Speaker Segments
Zack Kubow
executiveThanks, operator, and good afternoon to all of you. We appreciate you being with us for the Corvus Pharmaceuticals conference call covering our business update and financial results for the fourth quarter and the full year 2025. Here to talk through the results and business updates are Richard Miller, our Chief Executive Officer, Leiv Lea, our Chief Financial Officer, Jeff Arcara, our Chief Business Officer, and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. Our executive team will begin with some prepared remarks, and after that we'll take questions. I want to remind all of you that today's comments from management, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could cause actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus's annual report on Form 10-K for the year ended December 31, 2025, and in other filings the company makes with the SEC from time to time. Unless the law requires it, the company assumes no obligation to publicly update or revise any forward-looking statements; with that, I'll hand the call over to Leiv.
Leiv Lea
executiveThanks, Zach. I'll start with a quick look at how we did in the fourth quarter and across all of 2025 financially, and after that I'll hand things to Richard for an update on the business. R&D spending during Q4 2025 came to $9.9 million, versus $6 million in the comparable stretch of 2024. For the whole of 2025, research and development costs reached $33.7 million, up from $19.4 million across all of 2024. Those higher R&D figures in both the fourth quarter and the full year 2025 largely reflected greater clinical trial and manufacturing outlays tied to developing soquelitinib, plus rising personnel expenses. Our net loss in Q4 2025 came in at $12.3 million, against a net loss of $12.1 million during the matching period of 2024. Within the net loss for the fourth quarters of 2025 and 2024 were non-cash losses of $0.7 million and $2.2 million, respectively, stemming from Corvus's equity method investment in Angel Pharmaceuticals, along with a non-cash loss of $2.3 million in Q4 2024 tied to the change in fair value of the company's warrant liability. Stock compensation expense totaled $1.6 million for the three months that ended December 31, 2025, compared with $0.8 million in the equivalent period of 2024. At December 31, 2025, Corvus held cash equivalents and marketable securities amounting to $56.8 million, versus $52 million as of December 31, 2024; in January, we completed an upsized underwritten public offering featuring a premier group of biotech investors, bringing in net proceeds of $189 million. Once those net proceeds are factored in, pro forma cash as of December 31, 2025 stood at roughly $246 million, which pushes our cash runway into the second quarter of 2028. I'll now pass the call to Richard, who will walk through our clinical progress and go deeper on our strategy and plans.
Richard Miller
executiveThanks, Leiv, and hello to everyone this afternoon. We appreciate you being here for today's update call. During 2025, we achieved meaningful strides in moving forward the development of soquelitinib, our first-in-class selective ITK inhibitor, which is intended to rebalance or reset the immune system. A key highlight was the oral session at the ASH annual meeting where final results from our phase I/I-B trial in peripheral T-cell lymphoma were presented, along with the recent release of data from cohort 4 of our phase I atopic dermatitis trial, which demonstrated that soquelitinib might emerge as a leading therapy for atopic dermatitis and possibly other inflammatory diseases. Soon after that data release, we closed a $200 million financing, which reflected substantial investor enthusiasm for the opportunity surrounding soquelitinib and ITK inhibition, based on our strong data so far, its distinctive mechanism of action, and its wide potential to assist patients across many areas of medicine. Consequently, we are starting 2026 from a position of strength, with enrollment continuing in our phase III PTCL trial, our phase II atopic dermatitis trial that was recently initiated, and the chance to broaden into mid-stage trials for other significant inflammatory diseases, including hidradenitis suppurativa and asthma, later this year. According to our present plans and expected timelines, our cash runway reaches beyond key data readouts for every one of these programs. During today's call, I will summarize the highlights from our cohort 4 data release, give the latest on our plans to present further data from the trial at an upcoming medical meeting, and offer an update on our phase II trial. I will also go over our pipeline expansion plans and important upcoming milestones. The results from cohort 4 and the complete phase I trial indicate that soquelitinib's emerging clinical profile seems to offer considerable advantages within the treatment landscape for atopic dermatitis. 1, it is taken orally. 2, it possesses a novel mechanism of action that merges tissue-selective and target-specific precision with the ability to influence multiple inflammatory signaling pathways. Number three, its safety and efficacy hold up across a wide variety of patients, including individuals who've had systemic treatments before. Number four, the responses it produces last, and there's no rebound of disease. Based on what our market research shows, this kind of profile would be seen as a significant leap forward for people dealing with atopic dermatitis. Soquelitinib's data making its profile and potential even stronger is something we're very excited about. It shows one of the most robust EASI 75 outcomes following only 8 weeks of treatment, and because responses are durable with no disease rebound, that might pave the way for novel therapeutic strategies in immune diseases, among them the prospect of using soquelitinib as an intermittent therapy. Taking everything into account, if larger clinical studies continue to validate the profile we've seen so far, we think soquelitinib could end up very strongly positioned as one of the top choices for patients suffering from moderate to severe atopic dermatitis. Now I'll walk through the main points from the data we recently released. Starting with efficacy. In cohort four, which was randomized and placebo-controlled, with the drug given over a treatment period of eight weeks, the average percent reduction on EASI was 72%, compared with 40% on placebo, and that difference was statistically significant at 0.035. EASI 75 was reached by 75% of patients — 9 out of 12 — while an additional patient came in at EASI 74. EASI 90 was achieved by 25% of patients, and 33% got to IGA 0 or 1. Out of 12 patients, 11 achieved EASI 50. Only one didn't respond, and that individual had not benefited from previous treatment with both DUPIXENT and RINVOQ. Among those who hit EASI 90, two had previously shown resistance or lack of response to systemic therapies. On the placebo side, 20% got to EASI 75 — though that figure drops to 17% when you factor in two patients who skipped their day 56 assessment and, when checked afterward, never made it to EASI 75. Additionally, two placebo recipients required rescue medication due to disease flares, while nobody in the active group did. Both placebo patients who reached EASI 75 had no history of prior systemic therapies. Looking at the placebo group, none of the seven patients with prior systemic therapy reached EASI 75. In contrast, among the five active patients who had received prior systemic therapies, three hit EASI 75. What we saw in cohort 4 backs up what we hypothesized from cohorts 1 through 3: giving the treatment for a longer period leads to deeper responses. The data also demonstrate that soquelitinib beats placebo on every efficacy endpoint we looked at. And when we stack it up against other agents, our view is that the results so far position soquelitinib among the most active agents for atopic dermatitis — whether oral or injectable, approved or still in development. That brings me to highlight number two, durability. For cohort 3, we decided to be more methodical about tracking how long remissions lasted, using a blinded follow-up period after treatment that ran 90 days—longer than the 30 days we monitored in cohorts 1 and 2. What the cohort 3 results indicate is that the responses seen on day 28, which was the final day of dosing, either held steady or got somewhat better through 118 days, meaning 90 days with no therapy. By contrast, every other systemic treatment for atopic dermatitis shows disease rebounding quickly, beginning as early as one week after patients stop their medication. With soquelitinib, we are not observing any rebound effect, in either cohort 3 or cohort 4. Our hypothesis is that soquelitinib's triggering of T-regulatory cells may underlie the lasting inflammation control and continued remission we observe; preclinical studies have shown this, and biomarker findings indicate a rise in circulating Tregs among patients in cohort 3. Showing circulating Tregs is fairly striking, since under normal circumstances these cells appear in blood only very infrequently; most likely they are traveling toward and gathering within areas affected by disease, which is what we observed in our animal models. The third point is wide-ranging applicability. Among everyone who joined the phase I trial, 35% had undergone earlier systemic treatments, and that figure reaches 50% for those in cohort 4. The therapy used most often beforehand was dupilumab, with JAK inhibitors coming next, and a number of patients had gone through more than one earlier treatment. That takes in people whose last systemic therapy stopped working for them — put another way, they didn't respond to what they'd been given before. Usually, someone who's treatment resistant, or who's been through several earlier therapies, is a tougher case, and the placebo arm of the trial bore that out. Data from the response curves revealed that placebo recipients with prior systemic therapy fared worse than those without it, which points to earlier systemic treatment being an unfavorable characteristic. Even so, the response curves among patients on soquelitinib look much the same across those groups, which points to soquelitinib being unaffected by whether someone has had systemic therapy before. Along with the baseline characteristics of our patients, that also suggests the population treated under our protocol was more unfavorable than what's been reported in the majority of atopic dermatitis clinical trials. As mentioned earlier, among those with prior systemic therapies, EASI-75 came in at 0% for placebo — 0 out of seven — compared with 60%, or three of five, for those given soquelitinib; regarding patient indications, we conclude that soquelitinib is active in patients who've had prior systemic therapies, with outcomes no different from naive patients, even though these patients have more unfavorable disease.
Richard Miller
executiveWe saw responses in patients whose earlier systemic treatment had failed them. That backs up what we suspected about soquelitinib's unique way of working, and about resistance not building up just because someone has already been through other therapies. The fourth point is safety. In cohort 4, where treatment ran longer, at 8 weeks, we didn't pick up any fresh safety concerns. Across cohort 4 and the whole phase I study, adverse events that came back up look comparable between the placebo arm and the arm getting the drug. Labs didn't show anything meaningful out of range. Liver findings were clean, with no shifts in liver function tests. Infection rates came out alike for those on treatment and those on placebo, and the cases were mild. Let me add a few remarks about infection, since investors have raised questions about whether EBV might reactivate. Those questions trace to extremely uncommon case reports in the literature describing EBV infection among infants born with germline mutations in ITK; in a newborn, the immune system is still rudimentary, because T cells and B cells haven't taken shape yet. The immune system matures as development proceeds and as antigens are encountered. Having a germline mutation in ITK within that early, still-developing immune system is nothing like briefly shutting down the kinase domain of ITK using a small molecule drug in someone whose immune system is fully mature. Across our lymphoma, atopic dermatitis, and ALPS studies so far, more than 150 patients have received soquelitinib, and we have not observed a single serious infection of any type. That adds up to over 14,000 patient days of therapy, and a few patients have stayed on the drug beyond two years; among PTCL patients, the majority carry EBV along with other viruses like CMV; in our phase I lymphoma trial, more than 30 patients had EBV detectable in their blood at baseline — meaning prior to treatment — as measured by PCR, so they were viremic. Not one of those patients, nor any other patient, showed any sign of EBV reactivation or an illness tied to it while on treatment, which for some stretched past two years. Keep in mind, these patients are profoundly immunocompromised. One more point worth noting: inhibiting ITK leaves TH1 cells alone, something also called TH1 skewing. TH1 cells are the ones that clear out viruses. Beyond the clinical findings, we've now identified biomarkers that back up the novel mechanism of action, where ITK inhibition produces immune rebalancing. A number of these biomarkers amount to new discoveries. In short, the data reveal drops in IL-4, IL-5, and IL-17 cytokines, a slight decline in TARC, fewer Th2 cells, and more Tregs; in work still underway, we're also seeing very substantial and intriguing shifts in the JAK-STAT signaling pathways, which we'll report on at a later point. Given the extra information coming forward, from the clinic as well as our biomarker analysis — things like Treg induction — we think soquelitinib's novel mechanism of action, together with its safety, will make it useful across a range of indications in immune inflammatory diseases and in cancers. The abstract on soquelitinib got accepted for an oral presentation at the Society for Investigative Dermatology, or SID annual meeting, held in mid-May. At that session, the plan is to share phase I clinical data, adding to what we know about safety and durability. Biomarker findings will also be a key focus of the talk, and we think these will offer fresh perspectives on how immune diseases might be controlled. At AAD, our late breaker abstract wasn't chosen for a presentation, since that meeting usually leans toward trials at later stages. In China, our partner Angel Pharmaceuticals is currently enrolling its phase Ib/2 study in atopic dermatitis. It's a blinded, placebo-controlled design assessing a 12-week regimen across 48 patients, using soquelitinib at 100 milligrams BID, 200 milligrams QD, 200 milligrams BID, and 400 milligrams QD. Eligibility criteria and endpoints match those Corvus used. Based on what the phase I portion shows, another 60 to 90 patients could be added into the phase II portion. Leading centers in China, highly experienced with trials like this, have the study open. Work is being done in tight collaboration with the Corvus team. Data from the first cohorts should arrive late this year. Turning now to our phase II randomized placebo-controlled atopic dermatitis trial, which we announced today has begun. Enrollment is set for 200 patients with moderate to severe disease, split randomly among four cohorts of 50 patients each. Patients with prior systemic therapy use will be permitted. The doses under review are 200 milligrams QD, 200 milligrams BID, and 400 milligrams QD, plus placebo. Treatment runs 12 weeks, followed by 90 days off treatment for follow-up. Median percent reduction in EASI at 12 weeks serves as the primary endpoint, a standard one for phase II atopic dermatitis studies. Additional endpoints cover EASI-75, EASI-90, IGA, PP-NRS, and more. This study will span internationally. We expect data from it to be ready in mid-2027. Beyond atopic dermatitis, enrollment continues in our phase III registration PTCL trial, with an interim analysis anticipated later this year. A scheduled meeting of our outside independent data safety monitoring board recently took place. No safety signals came up, and the trial proceeds as planned. In December, at the American Society of Hematology, or ASH, annual meeting, we shared final data from our phase I/I-B clinical trial of soquelitinib in T-cell lymphoma patients. Those results back the ongoing phase III program, indicating that patients in the 200 milligram BID cohort, the same dose under study in phase III, achieved a median progression-free survival of 6.2 months and a median overall survival of 28 months, which compares favorably, very favorably, against outcomes from other therapies. As an example, chemotherapy yields median survivals under one year, with PFSs under three and a half months. At ASH, the data that was presented additionally demonstrates soquelitinib's immunobiological impacts, along with how it works—affecting T-cell differentiation through ITK inhibition. Such findings back its potential in atopic dermatitis as well as in a far wider array of immune and inflammatory conditions. From our ALPS, meaning autoimmune lymphoproliferative syndrome, clinical trial, we likewise keep gathering highly encouraging data, and 3 patients have now been receiving therapy for nearly 12 months. Our collaboration with the NIAID team is ongoing, and right now we intend to submit data for a possible presentation about the study at the ASH meeting in December. Regarding trials that are coming up, later this year we plan to launch a phase 2 study of soquelitinib in hidradenitis suppurativa and asthma. There's a compelling scientific basis for testing soquelitinib in HS, a disease driven by IL-17. In both in vitro and in vivo animal models, soquelitinib strongly inhibits Th17 cells and lowers IL-17 production. For HS, our trial design is at a more advanced stage. Broadly speaking, we intend to enroll roughly 60 patients in total who have moderate to severe HS, split across three arms: 200 milligram BID, 400 milligram QD, and placebo. Treatment will last 12 weeks, and the primary endpoints are safety and efficacy as measured by HiSCR50 and HiSCR75.
Richard Miller
executiveThe design for the asthma trial is taking shape, and it will probably include roughly 150 patients who receive treatment across three months. To wrap up, we have growing confidence in what soquelitinib could achieve over the long term in atopic dermatitis, peripheral T-cell lymphoma, and a wide array of other inflammatory conditions. We have only just started to reveal everything that ITK inhibition and immunomodulation might be capable of, and that could produce novel, improved treatments for inflammatory, autoimmune, and fibrotic diseases as well as cancers. With soquelitinib and our ITK platform, we are generating considerable momentum, and we are eager to share updates on our progress with you over the course of the year. At this point, I will hand the call to the operator so we can begin the question and answer session. Operator?
Roger Song
analystExcellent. Appreciate you letting us ask something, and well done on everything you've accomplished so far.
Richard Miller
executiveMm-hmm.
Roger Song
analystRoger, one thing I'd like to ask about concerns what we'll learn from the data you'll be getting ahead of the phase II — that global interim that's coming in the US around the middle of next year. There's the potential PTCL data, plus the twelve-week study results from China. From both an efficacy and a safety standpoint, how should we be interpreting what comes out of those readouts as they relate to the phase II AD, especially where the 400 milligram QD high dose is concerned? Thanks.
Richard Miller
executiveAlright. So what we expect is that Angel Pharmaceuticals — they're the ones running a placebo randomized trial and evaluating a range of doses — will come out with data from their first few cohorts before this year is over. That's readout number one, and it'll cover 100 milligrams BID along with 200 milligrams QD. Keep in mind that their treatment period runs 12 weeks, whereas we've only gone as far as 8 weeks. This is going to be really valuable for us. That data comes unblinded; they review it, and then we're able to report it. Then the following portion of the study examines 200 milligrams BID and 400 QD, likely around the middle of 2027. Right? We'll be getting information on a larger set of patients and so forth. After all that, Angel continues onward and enrolls 40 or 50, 60 or 60 to 90 patients into a phase II study, moving straight into it. Altogether, you're talking roughly 140 patients or thereabouts — well, yes, 130, 140 patients. That whole thing wraps up by mid-2027 or early 2027. Some data from them will arrive late this year, with additional data during the first half of 2027. As for the PTCL trial, a formal interim review happens later this year. A futility analysis forms one component of that, along with a safety analysis. Full results from the trial, though, are anticipated in late 2027. Right? And what I mentioned during the call is that we also have periodic safety reviews conducted outside by independent reviewers for the phase III PTCL trial. One of those took place quite recently, and as I said, everything came back looking good.
Roger Song
analystThank you.
Richard Miller
executiveOkay.
Li Watsek
analystHello, everyone. We appreciate you fielding our questions as well. To start, regarding the information that will be shared at the SID conference in May — Richard mentioned earlier both biomarker and durability findings. Could you perhaps help us understand what we should anticipate?
Richard Miller
executiveSure, I can give you a sense of what to expect. Durability is still holding up very well. On the biomarker side, beyond the ones I've already talked about, we've turned up several additional biomarkers, and that will likely make up the bulk of what we present at SID. There's really compelling work involving T-regulatory cells and certain JAK-STAT signaling. The takeaway is that multiple cytokine pathways are being influenced. You're going after one specific enzyme confined to T cells, yet that can still impact a number of distinct cytokines, and every one of them matters in inflammatory conditions such as IL-5, IL-4, IL-17, and so on. We'll also provide an update on the clinical data covering durability along with a handful of other items.
Li Watsek
analystMy second question.
Richard Miller
executiveAll right.
Li Watsek
analystApologies. For my next question, I'd like to ask about the phase II study in HS. I'm just curious about the benchmark you have in mind, particularly when compared with approved agents in this area, such as IL-17. In terms of efficacy, do you feel that matching the biologics is necessary?
Richard Miller
executiveOkay, so to start with, we need to determine the best dose, and that means testing a few different ones. Naturally, the AD study gives us information, and the T-cell lymphoma study also gives us information for the HS trial. My expectation is that efficacy will be at least as good as, or possibly better than, what already exists. That refers to the corrected HiSCR scores, which are around 25%, right?
Graig Suvannavejh
analystHello, Richard. Congratulations on the impressive strides soquelitinib is making in several indications, and I appreciate you fielding my questions. There are a few points I hoped to bring up. To start, regarding upcoming data presentations, you mentioned possibly submitting a late breaker abstract to AAD. I believe you explained why your abstract might not have been accepted. That said, I'm fairly sure Kymera does have a late breaker. I'm not familiar with their dataset, since I don't cover it, so it isn't something I can recall offhand. Do you have any idea whether it's because they had a larger database? Because I do believe their abstract is. I'm just wondering if you had any perspective on that?
Richard Miller
executiveWell, Graig, when it comes to what gets accepted—abstracts that get accepted, or even publications that get accepted—this is a capricious process. Many factors are at play. I don't know why some are accepted and others aren't. Personally, I'm shocked that the Kymera one, with no placebo and an interesting study, for sure, but you know, I don't have an explanation for it.
Graig Suvannavejh
analystPerhaps there isn't a solid one. I was merely thinking out loud. Have you done any thinking along those lines?
Richard Miller
executiveHonestly, I wouldn't stress over it much. What I mean is, some truly excellent papers of mine have gotten into certain journals while being turned down by others. At the end of the day, it comes down to a couple of people scanning a few abstracts. I did that kind of work myself years ago. You're handed several hundred to evaluate, and then you make a call on what seems worthwhile, more or less. So I'm not sure I'd read too much into any particular explanation for that. Our presence at AAD is minimal. Nothing has ever been done by us there. Booths aren't something we have. Their journals aren't something we, you know, pay for. That, I think, could be one more element. Might be one more element. I can't say for certain. In any case.
Graig Suvannavejh
analystAll right.
Richard Miller
executiveThe SID conference is a solid one. If anything, it's more scientifically demanding. This is where early stage, translational biology, and research get showcased; I believe we ultimately landed in a really strong position.
Graig Suvannavejh
analystAll right, excellent. Could I just ask about the phase II AD study that you've kicked off — congrats on that, by the way. I believe you said results should come out around the middle of 2027, and I'm just curious whether, between today and mid-2027, there might be a chance for the company to give some form of update. I'm simply trying to get a feel for the news flow coming out of that trial from now through mid-2027.
Richard Miller
executiveThat phase II study is randomized, placebo-controlled, and blinded. No, we won't get a look at those results until the trial finishes. As I said, the Angel trial is up and running. It's blinded and placebo-controlled as well, though they're able to review the results following every cohort, much like we did in our phase I. That one will generate news flow when it comes to the AD side of things.
Graig Suvannavejh
analystOkay.
Richard Miller
executiveOkay?
Graig Suvannavejh
analystIf I may, one final question — it concerns hidradenitis suppurativa, since I do provide coverage of a few other firms. My understanding is that HS lacks any really solid preclinical models.
Richard Miller
executiveYou've got that right.
Graig Suvannavejh
analystSo I'm curious — in HS, where reliable or well-validated predictive models may not really exist, how would you gauge the odds of success? Thanks.
Richard Miller
executiveThat's right. For HS, we lack solid animal models. Human data make it quite evident that IL-17 matters a great deal. Th17 and IL-17 play a major role. In fact, IL-17s have approval for treating this condition. I'd say proof of principle exists already: block IL-17, and it ought to work. Among the numerous other cytokines we target, we also block IL-17. Hidradenitis suppurativa involves many kinds of inflammatory cells — T cells, neutrophils, B cells, to name a few. Once more, my view is that soquelitinib's benefit comes from hitting several cytokine pathways at once, so you end up influencing numerous lineages, a wide range of lineages, and I believe that will matter. After all, when you examine where the disease sits, even in atopic dermatitis, what you observe is, well, not merely Th2 cells — you observe plenty of varied cells.
Graig Suvannavejh
analystThanks.
Richard Miller
executiveHonestly, the way I'd put it is this: anti-IL-17 does work in that condition, and our blockade of it is even stronger.
Graig Suvannavejh
analystThanks a lot.
Jeff Jones
analystHi everyone, afternoon, and appreciate you taking my question. Given that we've probably discussed HS more than enough, perhaps we could shift to AD and where things stand for you. This involves a separate condition and indication compared with the dermatological ones. What's your thinking on dosing within your approach for that?
Richard Miller
executiveI believe you're probably referring to asthma.
Jeff Jones
analystAsthma—my mistake.
Richard Miller
executiveRight, right. You brought up AD. Well, as you're aware, atopic dermatitis and asthma often appear together, and medications effective for one frequently prove effective for the other; they appear to belong to the atopic syndromes. We have a number, and that's one for which we actually possess a number of animal models, and our drug performs very well in those asthma models. Four or five distinct models—soquelitinib works beautifully. Regarding dosing, I believe it's the identical dosing we've discussed. The AD and PTCL studies provide information for the asthma. The asthma study employed essentially the same dosing regimens. There'd be no reason to change that.
Jeff Jones
analystAlright, I've got a question about
Richard Miller
executiveLet me expand on that a bit. Keep in mind that we possess the finest biomarker available anywhere, namely that one, and this is something we've done for many years. The drug can be administered, then you extract the T-cells from the patient — whether from blood or from disease sites — and you're able to quite precisely quantify the drug that's located in the target. This is a clean quantitative assay. It prevents that enzyme from functioning. That constitutes a biomarker. When a 200 milligram dose is given, we know that it essentially achieves full blockade of that. My apologies, Jeff.
Jeff Jones
analystAppreciate that, Richard. About the ALPS study you've got going with the NIH — could you talk a bit about how the findings there might influence the way you think about other indications, or steer what the team's working on?
Richard Miller
executiveWith ALPS, you've got an autoimmune response that overreacts to a whole range of different things. You get antibodies developing against red cells, white cells, platelets, and other components; and in ALPS along with lymphocyte proliferation, you find abnormal lymphocytes. In the patients we've treated, the outcomes have been quite compelling. What that's teaching us — similar to the lessons from lymphoma — is that this drug shows strong activity, has a good safety profile, and is disrupting the signaling pathways we'd expect it to. So I can't just say that success in ALPS means success in lupus, despite the fact that the mouse version of ALPS serves as a model for SLE. That isn't the way we approach this. What it represents for us is a signal that we're impacting abnormal autoinflammatory reactions in an illness that currently lacks solid treatment options — it functions somewhat as a model, though a human one. This is an orphan condition. Effective therapies don't exist. Might approval be achievable for ALPS? Absolutely, that's possible. It tends to affect children more often. Our treated population has been adults. Our plan is to expand the site count, and within roughly the next twelve months we also plan to shift downward in age to include children. We've had discussions with NIH regarding this. That represents a separate indication, and it's an autoimmune disease as it happens.
Jeff Jones
analystAll right. That's helpful — thank you, everybody.
Aydin Huseynov
analystHi, Richard — congratulations on how much headway you've achieved with the soquelitinib pipeline over this quarter. I've got a handful of things to ask. To begin: regarding the near-term readout — the interim analysis coming from the phase III study in PTCL — could you share anything about how enrollment is progressing? Which subtypes of PTCL are in fact being enrolled? Is NOS among them? What about ALCL, follicular, cutaneous? Also, what are physicians turning to as standard of care? Do they favor belinostat or pralatrexate? I'm simply interested in how the trial is behaving overall.
Richard Miller
executiveOkay. That's the one we'll take first. Recruitment is still underway, and every aspect is proceeding according to schedule. Study participants get assigned randomly to receive either soquelitinib by itself at a dose of 200 milligrams BID, or whichever therapy the treating physician selects between belinostat and pralatrexate. Now, it's worth remembering that those two drugs — belinostat and pralatrexate — received conditional approval, an accelerated approval, about 15 years back, and that decision rested on how well patients with relapsed PTCL responded. When we spoke with FDA, that comparator was the sensible one. Soquelitinib against those two options. Now, the study isn't blinded, since that simply isn't possible. For one thing, blinding is not something we typically do in oncology, and beyond that, you obviously can't mask an oral drug like soquelitinib, as everyone understands. Both belinostat and pralatrexate come in through IV lines, and they carry the standard chemo side effects — mouth sores, issues with blood cell counts, that sort of thing. Enrollment in the study is still ongoing at this point. We've held our initial safety monitoring board meeting, and no fresh or distinct safety concerns came up regarding soquelitinib. Clearly it's far less dangerous than chemo — on every measure, we come out ahead there. As for who's being enrolled, per the protocol it's PTCL NOS patients, which is the most frequent type. We also permit anaplastic lymphomas that test ALK-positive. Then there's the other major group, known as T follicular helper, which previously went by the name AITL, or angioimmunoblastic lymphoma. CTCL isn't part of this. The reason we're leaving it out of the study is that CTCL behaves more like a chronic condition and gets managed with a different approach. That's fairly standard. The subtypes enrolled here represent the peripheral T-cell lymphomas seen most often. And once more, for everyone's benefit: when peripheral T-cell lymphoma comes back after treatment, no therapy has full approval. Take median PFS — for belinostat it sits at 1.7 months. With pralatrexate you get 3 months. Overall survival figures fall short of one year. Those numbers are dreadful; this is a dreadful disease. The people affected are very ill. What I can share is that the way this trial is progressing makes us extremely pleased. If the study concludes and delivers the outcomes we anticipate, I believe this may prove to be a major advance in hematology. Is that what you were asking? What—
Aydin Huseynov
analystYeah. Thanks so much.
Richard Miller
executiveYeah.
Aydin Huseynov
analystAppreciate that.
Richard Miller
executiveYeah.
Aydin Huseynov
analystThere's a further item I'd like to raise regarding asthma, should that be acceptable.
Richard Miller
executiveOf course.
Aydin Huseynov
analystWhen it comes to how the asthma trial will be designed that's coming up, are you intending to include a group of patients who might have atopic dermatitis along with asthma? From where you stand, could there be any faster route using a small pivotal study for people dealing with both conditions at once? Basically, that would make it possible for soquelitinib to treat two illnesses simultaneously.
Richard Miller
executiveMm-hmm.
Aydin Huseynov
analystTo our understanding, DUPIXENT stands alone as the single medication addressing both of these conditions.
Richard Miller
executiveCorrect.
Aydin Huseynov
analystPerhaps it could all be done at once.
Richard Miller
executiveThat would be wonderful, though I'm not sure. To begin with, getting two indications from a single effort is genuinely quite challenging. Sure, you might gather anecdotal reports. I'm aware that certain individuals mention this. We ourselves have come across some anecdotal reports regarding it. The trouble is, there's no way to know how many patients will present with both conditions simultaneously, how serious it is, which metrics will be applied, or how you'd calculate statistical power for every condition. That's genuinely tough to pull off. From anecdotal experience, it's something worth examining. A separate trial is necessary. Even DUPIXENT had, as you know, distinct trials for asthma, eosinophilic esophagitis, COPD, and every one of those. A separate trial is required. Now, one item we're weighing — and we're genuinely quite intrigued by — would be, I'd say, two items. The first is that this durability of response is pretty compelling. We believe we can account for it. In my view, we possess a strong immunologic rationale for it. It's quite refined, and it aligns with what is understood regarding immune responses and similar matters; we're also highly impressed by the activity observed among patients for whom earlier treatments had failed. And I brought that up during my remarks here; we are permitting — and I'm unsure whether I said this — patients whose prior therapies failed into our phase II atopic dermatitis study. A number of individuals, many investors, keep asking me, "Why not run a distinct study focused on resistant atopic dermatitis patients?" That's a possibility we're contemplating. As you know, that might be a smaller trial, since efficacy and placebo perform so poorly, you'd presumably demonstrate a larger difference using fewer patients; even so, we're enrolling both naive and experienced patients in our phase II. I'd take the same approach in phase III, which would let you capture the entire patient population. Without question, as additional therapies keep emerging for atopic dermatitis, the share of patients who aren't treatment naive — meaning those whose earlier therapies failed — that pool keeps growing. The naive patient pool will shrink proportionally. Alright. So the resistant patient is becoming, in my view, quite appealing. I mean, there's plenty about soquelitinib that excites us. It's oral, it's safe, and all the rest of it. The durability, I believe, is a game changer — it alters the way you tackle the disease. I think the reality that, you know, one could consider frontline therapy, relapsed disease, or multiple therapies, you know, intermittent therapy. That's how we, you know, that's the way we look at it.
Aydin Huseynov
analystThat tracks. OK, thank you very much. That's really useful, and congratulations on the results.
Sean Lee
analystHello, good afternoon, everyone, and I appreciate you fielding our questions. To dig into the durability question a little further, I believe in that earlier phase one trial, you monitored patients for as long as three months. In phase two, what's the follow-up period for these patients? Does the study have any power to genuinely distinguish between levels of durability for this response?
Richard Miller
executiveWithin the phase II study, there's a provision for keeping the trial blinded continuously through 90 days past the therapy. That means 12 weeks of treatment along with the 90-day follow-up period. All of that is written into the protocol. But the endpoint itself is the EASI score versus placebo at 12 weeks, which is the standard endpoint. Doing anything else would be, you know, somewhat unusual. My sense is that down the road, this question of how long responses last is something one could, you know, examine in a separate study. It seems logical to me. I mean, we'll discuss this further, but, you know, more than 90% of the patients we've treated don't relapse. In follow-up right now, stretching to 3 months past the final dose, more than 90% of patients, the disease simply doesn't return. Now, when you consider other agents, DUPIXENT, STAT6, STAT whatever, the IL-13s, IL-2s, whatever, those diseases return quite fast; from my perspective, that isn't a particularly good therapy. The best therapy is, you know, a shorter course of treatment. Disease resolves, and you don't have to take your drug again for an extended period, if ever. With luck. That's a big ask. Durability matters because it's important to grasp why it's occurring. Does it apply to other inflammatory diseases? Put differently, how wide is that going to be? Is it specific to atopic dermatitis, or is it something one could consider for other autoimmune diseases? You know, that's what makes us excited about it. In any case, to answer your question, in the phase II, it is included in the formal follow-up in a blinded manner, but it isn't part of the statistical endpoint. The statistical endpoint is the standard one, which is EASI score at the 12 weeks.
Sean Lee
analystAll right, that makes sense, appreciate the answer. For our next question, about the asthma trial that's coming up, will the focus be on eosinophilic asthma with Th2 high, or are you also going after the tougher-to-treat Th17-driven group?
Richard Miller
executiveThose are among the topics we're weighing at the moment. Our inclination is to include all patients.
Sean Lee
analystGot it. Turning to what's coming up,
Richard Miller
executivehonestly, Sean, I'm happy you raised that point, since there's a thing here. There are those who claim, "Well, the only disease you treat is Th2." Where that notion comes from, I have no idea. Others will say, "Oh, the only atopic dermatitis patients you're picking are the ones who are Th2." To begin with, I wouldn't even know a way to pull that off. It isn't what we're doing. The atopic dermatitis patients we have are, you know, ordinary patients coming from U.S. centers. You know, they must meet the required eligibility criteria, but no patient population got enriched on our end. By the way, for most of our AD patients, eosinophilia is absent. Their counts of eosinophils come in normal or low. My view is that we won't limit things to high EO asthma. That said, I should admit the protocol for the asthma study isn't final yet and discussion on it continues. Okay.
Sean Lee
analystUnderstood. Yes, that's quite useful. Thanks once more for answering what we asked.
Richard Miller
executiveVery well. Okay then, to start with, I appreciate all of you joining this call. We're eager to keep you informed over the remaining months of this year and afterward. Grateful for everyone's attention. Thanks.
Operator
operatorEveryone, that brings today's conference call to a close. We appreciate all of you joining us, and at this point you're free to hang up. Have a wonderful day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.